Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04484064 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Optimization of the Targeted Anticancer Therapies

Study acronym: OpTAT
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 23, 2020 (before its estimated December 2020 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The study includes an observational pharmacokinetic study and an interventional medication adherence study. The purpose of this study is 1) to describe the concentration-time profiles of targeted anticancer drugs and to characterize the concentration-effect/toxicity relationships in the target population of patients (observational study) and 2) to characterize patterns of adherence to oral targeted anticancer drugs and identify key-driver modifiable adherence factors in patients participating in an adherence program (interventional study).
Trial Details
NCT Number NCT04484064
Lead Sponsor Centre Hospitalier Universitaire Vaudois
Collaborators: Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland, Krebsforschung Schweiz, Bern, Switzerland
Conditions
(from sponsor)		 Cancer
Related terms Medication Adherence, Neoplasms
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov